NASDAQ: PPCB
Propanc Biopharma Inc Stock

$1.89-0.05 (-2.58%)
Updated Nov 16, 2026
PPCB Price
$1.89
Fair Value Price
N/A
Market Cap
$1.98M
52 Week Low
$1.63
52 Week High
$315.00
P/E
-0.02x
P/B
0.28x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$22.61M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.46
Operating Cash Flow
-$6M
Beta
2.51
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

PPCB Overview

Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine PPCB's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
PPCB
Ranked
Unranked of 450

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important PPCB news, forecast changes, insider trades & much more!

PPCB News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PPCB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PPCB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PPCB is good value based on its book value relative to its share price (0.28x), compared to the US Biotechnology industry average (5.03x)
P/B vs Industry Valuation
PPCB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PPCB due diligence checks available for Premium users.

Valuation

PPCB fair value

Fair Value of PPCB stock based on Discounted Cash Flow (DCF)

Price
$1.89
Fair Value
$0.70
Overvalued by
171.00%
PPCB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PPCB price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.02x
Industry
18.86x
Market
39.84x

PPCB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.28x
Industry
5.03x
PPCB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PPCB's financial health

Profit margin

Revenue
$0.0
Net Income
-$8.6M
Profit Margin
0%
PPCB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$10.3M
Liabilities
$3.3M
Debt to equity
0.46
PPCB's short-term assets ($8.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PPCB's short-term assets ($8.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PPCB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.0M
Investing
$0.0
Financing
$1.4M
PPCB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

PPCB vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
PPCB–$1.98M-2.63%-0.02x0.28x
ELAB–$1.94M+5.06%-0.00x0.16x
KAPA–$1.91M-10.35%-0.20x0.49x
CLDI–$2.08M-3.22%-0.14x1.27x
DCOY–$2.15M-7.59%0.03x0.47x

Propanc Biopharma Stock FAQ

What is Propanc Biopharma's quote symbol?

(NASDAQ: PPCB) Propanc Biopharma trades on the NASDAQ under the ticker symbol PPCB. Propanc Biopharma stock quotes can also be displayed as NASDAQ: PPCB.

If you're new to stock investing, here's how to buy Propanc Biopharma stock.

What is the 52 week high and low for Propanc Biopharma (NASDAQ: PPCB)?

(NASDAQ: PPCB) Propanc Biopharma's 52-week high was $315.00, and its 52-week low was $1.63. It is currently -99.4% from its 52-week high and 15.95% from its 52-week low.

How much is Propanc Biopharma stock worth today?

(NASDAQ: PPCB) Propanc Biopharma currently has 1,048,247 outstanding shares. With Propanc Biopharma stock trading at $1.89 per share, the total value of Propanc Biopharma stock (market capitalization) is $1.98M.

Propanc Biopharma stock was originally listed at a price of $717.50 in Aug 15, 2025. If you had invested in Propanc Biopharma stock at $717.50, your return over the last year would have been -99.74% (not including any dividends or dividend reinvestments).

How much is Propanc Biopharma's stock price per share?

(NASDAQ: PPCB) Propanc Biopharma stock price per share is $1.89 today (as of Nov 16, 2026).

What is Propanc Biopharma's Market Cap?

(NASDAQ: PPCB) Propanc Biopharma's market cap is $1.98M, as of Nov 17, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Propanc Biopharma's market cap is calculated by multiplying PPCB's current stock price of $1.89 by PPCB's total outstanding shares of 1,048,247.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.